Clinical trials: Invasive Pneumococcal Disease
Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease
Understanding Pneumococcal Carriage and Disease 2017-2020
Streptococcus pneumoniae is a type of bacteria that is carried (lives) in the nose of most individuals and can sometimes go on to cause severe infections such as meningitis and pneumonia.
- Conditions
- Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease, Streptococcal Pneumonia
- Trial name
- NCT03102840
- Testing
- Nasopharyngeal swab, blood sampling
- Where
- United Kingdom
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- University of Oxford
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults
The goal of this clinical trial is to learn if whole-cell Streptococcus pneumoniae (wSp) vaccination is safe and tolerated in healthy adults. The main aim is to evaluate the safety and tolerability of wSp vaccine.
- Trial name
- STREPTO VAC I (NCT07059182)
- Testing
- Inactivated whole-cell Streptococcus pneumoniae vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Streptococcus Pneumonia, Streptococcus Pyogenes Infection
Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection
As Covid 19 manifestations that have been recently described, inflammatory manifestation have major impact in infectious disease lesions.
- Conditions
- Streptococcus Pneumonia, Streptococcus Pyogenes Infection, Neisseria Meningitides Meningitis
- Trial name
- RIPI (NCT04594785)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Montpellier
Invasive Pneumococcal Infections, Sickle Cells Disease
Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease
Streptococcus pneumoniae is the major cause of bacterial infection in patients with sickle cells disease. The 23-valent pneumococcal polysaccharide vaccine (PSV) is supposed to be poorly immunogenic in these patients.
- Trial name
- DREVAC (NCT02274415)
- Testing
- Vaccination with the combined vaccine (Prevenar13 ®), Vaccination with the polysaccharide vaccine (Pneumo 23 ®)
- Where
- France
- Volunteers
- 116 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumococcal Infections
Surveillance of Invasive Pneumococcal Infections in Adults (Excluding Meningitis)
Given the frequency and severity of invasive pneumococcal infections and questions about the place of VPC-13 in the prevention of pneumococcal infections in adults based on the presence of risk factors, current laboratory…
- Trial name
- SIIP (NCT03983616)
- Where
- France
- Volunteers
- 1,560 people
- Sponsor
- University Hospital, Limoges
Pneumonia, Meningitis
Colombia Epidemiologic Surveillance Study
The study will determine the reduction in invasive pneumococcal disease (IPD) after the introduction of a National Immunization Program with PCV-7 in Bogota.
- Conditions
- Pneumonia, Meningitis, Bacteremia, Sepsis
- Trial name
- LEAP II (NCT00428051)
- Testing
- Surveillance
- Where
- 3 sites in Brazil, Colombia and 1 more
- Volunteers
- 32,867 people
- Sponsor
- Pfizer
Invasive Pneumococcal Disease
Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
The primary purpose of this study is to evaluate the immune response to 13-valent pneumococcal conjugate vaccine (13vPnCV) in children who as infants received either a complete series of PnCV versus a combination of PnCV and…
- Trial name
- REPLAY (NCT00853749)
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), Blood draw
- Where
- 2 sites in Iceland
- Volunteers
- 89 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65 years of age and in Indian children 6 to 17 years of age.
- Trial name
- NCT02034877
- Testing
- 13-valent Pneumococcal conjugate vaccine, Blood sample collection
- Where
- 16 sites in India
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sickle Cell Disease (SCD), Invasive Bacterial Infections
Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025
Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complications. Preventive measures, including antibiotic prophylaxis and vaccination, have changed the epidemiology of…
- Trial name
- DREPIBAC (NCT07639008)
- Where
- 31 sites in France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumococcal Disease, Invasive, Pneumococcal Disease
Serum Collection Study for Assay Development
The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation
- Trial name
- NCT07205289
- Testing
- Gamma-PN
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Invasive Pneumococcal Infection
Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy
The study hypothesis is that a "reinforced" pneumococcal combined vaccine strategy in patients with ANCA-associated vasculitides treated with rituximab will induce a better immune response than the current standard regimen, with…
- Trial name
- PNEUMOVAS (NCT03069703)
- Testing
- PCV13, PPV23, Rituximab
- Where
- France
- Volunteers
- 96 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer
Invasive Pneumococcal Disease
7-valent Pneumococcal Conjugated Vaccination
Hypothesis: the efficacy of 2 doses 7-valent PCV is equivalent to 1 dose 7-valent PCV.
- Trial name
- PCV (NCT00885625)
- Testing
- 7-valent pneumococcal conjugated vaccine
- Where
- Taiwan
- Volunteers
- 350 people
- Sponsor
- National Taiwan University Hospital
Pneumococcal Diseases
Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey
The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae that causes invasive diseases at children and adults in Turkey.
- Trial name
- NCT01810861
- Testing
- There is no intervention in this study
- Where
- 32 sites in Turkey (Türkiye)
- Volunteers
- 922 people
- Sponsor
- Pfizer
Pneumonia, Pneumococcal
Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)
To explore a further dimension of susceptibility to disease, the investigators tested the hypothesis that natural variation exists in the rapidity of IgG responses following exposure to pneumococcal polysaccharides, and that…
- Trial name
- NCT03460730
- Testing
- Pneumovax
- Where
- Kenya
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Invasive Pneumococcal Infection
Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection.
Respiratory tract infections are among the leading causes of death worldwide and many of these infections are preventable through vaccination.
- Trial name
- pVax (NCT06334185)
- Volunteers
- 320 people
- Sponsor
- Azienda Ospedaliera di Lecco
Infections, Streptococcal
Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population
As the licensed pneumococcal vaccine is not always satisfactory in elderly, new investigational pneumococcal vaccines are evaluated in the healthy elderly population.
- Trial name
- NCT00327665
- Testing
- 11-valent pneumococcal vaccine GSK513026, Pneumo 23™, 10-valent pneumococcal vaccine GSK513026
- Where
- 3 sites in Belgium, Finland and 1 more
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years
The purpose of this study is to identify the S. pneumoniae serotypes strains and to determine antibiotic susceptibility.
- Trial name
- Pneumococci (NCT00843895)
- Testing
- pneumococcal conjugate vaccine(prevenar)
- Volunteers
- 400 people
- Sponsor
- King Saud University
Pneumococcal Disease, Invasive
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13)…
- Trial name
- NCT05934890
- Testing
- Walvax PCV13-TT, Pfizer PCV13
- Where
- 2 sites in Indonesia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.